Studie

Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies

Erkrankungsgruppe:

ZNS und Gehirntumore

Organsystem:

Zentrales Nervensystem

Stadium:

Ersterkrankung

Standort:

Essen

EudraCT:

2016-004441-82

Prüfplan-Code:

CA209-908

Phase:

I/II

Prüfsubstanz:

Nivolumab + Ipilimumab

Sponsor:

BMS